Crossmark

U.S. Food and Drug Administration’s Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression

Crossref DOI link: https://doi.org/10.1007/s43441-021-00340-6

Published Online: 2021-10-08

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Katz, Eva G. https://orcid.org/0000-0002-6293-1674
McNulty, Pauline

Levitan, Bennett

Treichler, Patricia

Martynowicz, Jadwiga

Jamieson, Carol
Funding

Funding for this research was provided by:

Janssen Research and Development, LLC
License Information

Text and Data Mining valid from 2021-10-08

Version of Record valid from 2021-10-08
More Information

Article History

Received: 7 April 2021

Accepted: 19 September 2021

First Online: 8 October 2021

Declarations

:

: All authors are employees of Janssen Research & Development and may own stock and/or stock options. BL has a stocks portfolio that at times includes other pharmaceutical and health care-related companies.

Document is current

Any future updates will be listed below